Cassava Sciences, Inc. (SAVA)

In November 2024, Phase 3 trials of simufilam failed, leading to its discontinuation for Alzheimer's and an 85% stock price drop. In November 2025, the CEO's stock buy led to a 10% stock rise after market close. In December 2025, the FDA placed a clinical hold on simufilam for TSC-related epilepsy, causing a 24% stock slide, and the company settled securities class action litigation. In January 2026, the stock price was $2.05, representing a -1.91% loss over the previous two weeks and a decline of 23.08% from January 13, 2025.

As a clinical-stage biopharmaceutical company, Cassava Sciences, Inc. does not have approved products on the market and therefore does not experience traditional product demand seasonality. However, historically, buying Cassava Sciences Inc (SAVA) stock in January has shown the highest probability of a positive return (60.00%), while March has the lowest probability (25.00%).

Cassava Sciences, Inc., based in Austin, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies and diagnostics for neurodegenerative diseases, primarily Alzheimer's disease and TSC-related seizures. Its lead therapeutic product candidate, simufilam, was discontinued for Alzheimer's disease in November 2024 after failing Phase III clinical trials. The company also has an investigational diagnostic product candidate called SavaDx. As a clinical-stage company, Cassava Sciences had no product revenues between 2013 and 2021, focusing purely on research and development.

Cassava Sciences, Inc. is headquartered in Austin, Texas. Clinical trials for simufilam have been conducted across multiple sites in the United States and Australia.

Cassava Sciences' brand reputation has been negatively impacted by an FDA inspection raising doubts about simufilam's trial results, the DOJ charging an advisor with fraud, resignations of key executives, SEC fraud charges against the company and executives, the failure of Phase 3 clinical trials for simufilam, and the DOJ dropping fraud charges against Hoau-Yan Wang. These events have led to a negative news sentiment for the company.

Cassava Sciences, Inc. has a mixed ownership structure, with institutional investors holding approximately 9.25% to 38.05% of the stock, including major shareholders like Vanguard Group Inc and BlackRock, Inc. Insiders hold 6.25% to 12.20% of the stock, with Eastbourne Capital Management LLC and Remi Barbier holding substantial stakes. The general public holds a substantial portion, with some reports indicating up to 60% or 79.99% of shares. Insider buying has been observed in the past three months, with insiders buying $201,809.00 in company stock.